Furthermore, we discuss that stratification based on melanoma subtype might improve response rates to immune checkpoint blockade therapy (anti-PD-1/anti-PD-L1/anti-CTLA-4) and adoptive cell therapy. The gene discussed is PDCD1; the disease is melanoma.